Arsanis

@ArsanisInc

A leader in the discovery and development of mAbs for the targeted immunotherapy of serious infections. View our community guidelines:

U.S. & Austria
Vrijeme pridruživanja: studeni 2017.

Tweetovi

Blokirali ste korisnika/cu @ArsanisInc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ArsanisInc

  1. 27. stu 2018.

    We are excited to announce that we have entered into a definitive merger agreement with X4 Pharmaceuticals. Join our conference call at 8:30 a.m. ET. The live webcast can be accessed here:

    Poništi
  2. 9. stu 2018.

    Today we announced our Q3 2018 earnings. Read more here:

    Poništi
  3. 13. kol 2018.

    Today we announced our Q2 2018 earnings. Read more here:

    Poništi
  4. 10. kol 2018.

    Team Arsanis had a blast yesterday at the Dragon Boat Race with to support by addressing the impact of poverty and inequality. Donations are still being accepted until tomorrow!

    Poništi
  5. proslijedio/la je Tweet
    10. srp 2018.

    One week from today, teams from will compete in DRAGON BOAT RACES to raise money for Life Science Cares. Place your bets now!

    Poništi
  6. 2. srp 2018.

    We're approaching and with novel science. Read more about our programs:

    Poništi
  7. 29. lip 2018.

    Our team is dedicated to delivering a new way to address critical infectious disease threats.

    Poništi
  8. 26. lip 2018.

    According to , more than 2 million people annually become infected with antibiotic-resistant bacteria, and more than 23,000 patients die as a direct result of these infections. We're working on new ways to prevent and treat these serious infections.

    Poništi
  9. 25. lip 2018.

    Our lead program offers a novel, non-antibiotic approach to the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. Read more about our programs and pipeline:

    Poništi
  10. 21. lip 2018.

    Ventilator-associated pneumonia places a significant burden on patients & the healthcare system, increasing costs by approx $40K per patient. Read about our targeted prevention approach, which could profoundly impact patient outcomes & healthcare spending.

    Poništi
  11. 18. lip 2018.

    Advances in our knowledge of bacterial pathogenesis have now opened new possibilities of expanding the use of to acute bacterial infections. Learn more about our pipeline and approach:

    Poništi
  12. 15. lip 2018.

    : Methicillin-resistant Staphylococcus aureus (MRSA), a.k.a the "superbug," is considered one of the top drug-resistant threats in the U.S., causing more than 11,000 deaths per year, according to

    Poništi
  13. 14. lip 2018.

    Today we announced the outlicensing of our preclinical stage klebsiella pneumoniae monoclonal antibodies from our ASN300 program. Read more here:

    Poništi
  14. 14. lip 2018.

    Join us for our presentation at "Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics Conference" today in Washington, DC.

    Poništi
  15. 12. lip 2018.

    We are developing monoclonal antibodies, or , to address specific bacterial and viral pathogens without the use of antibiotics. Learn more about our novel approach:

    Poništi
  16. 10. lip 2018.

    Attending the meeting in Atlanta this week? Hear Adriana Badarau's Oral Presentation: 3 - Characterization of A Spa/Sbi Cross-Reactive Human Monoclonal Antibody that is Protective against Staphylococcus aureus Bacteremia/Sepsis from 3:30-3:45pm ET

    Poništi
  17. 10. lip 2018.

    Attending the meeting in Atlanta this week? See Nikolina Trstenjak's Poster Presentation #145 - Adaptation of the Human-Specific S. Aureus Leukocidin, Lukgh, to Rabbits by Protein Engineering from 12:45-2:45pm ET

    Poništi
  18. 8. lip 2018.

    Attending the meeting in Atlanta this week? Hear Nikolina Trstenjak's Rapid Fire Talk 9 - Adaptation of the Human-Specific S. Aureus Leukocidin, Lukgh, to Rabbits by Protein Engineering at 2:05pm ET

    Poništi
  19. 6. lip 2018.

    Don't miss our Chief Development Officer, David Mantus, as he joins the New Development Strategies for Vaccines and Therapeutics for the Developing World panel today at 3:00 p.m.

    Poništi
  20. 5. lip 2018.

    Our Head of Business Development, Aaron Pelta, will share a corporate overview at the 25th BIO Annual Meeting in Boston today at 11:30 a.m.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·